Arbutus Biopharma Corporation stock is up 16.95% since 30 days ago. The next earnings date is Feb 29, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 8 December’s closed higher than November.
Arbutus Biopharma Corporation develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate. AB-836, an oral capsid inhibitor that suppresses HBV DNA replication, is in Phase Ia/Ib clinical trial targeted to hepatocytes.